NRSN
NeuroSense Therapeutics Ltd

3,592
Loading...
Loading...
News
all
press releases
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement PR Newswire CAMBRIDGE, Mass., Jan. 6, 2025 NeuroSense in...
PR Newswire·8mo ago
News Placeholder
More News
News Placeholder
NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS
NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS PR Newswire CAMBRIDGE, Mass., Dec. 23, 2024...
PR Newswire·9mo ago
News Placeholder
NeuroSense Provides Business Update and Third Quarter 2024 Financial Results
NeuroSense Provides Business Update and Third Quarter 2024 Financial Results NeuroSense Provides Business Update and Third Quarter 2024 Financial Results PR Newswire CAMBRIDGE, Mass., Dec. 18, 2024...
PR Newswire·9mo ago
News Placeholder
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC
NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC PR Newswire CAMBRIDGE, Mass., Dec. 11, 2024...
PR Newswire·9mo ago
News Placeholder
NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS
NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's...
PR Newswire·9mo ago
News Placeholder
NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price
NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price PR Newswire...
PR Newswire·9mo ago
News Placeholder
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND PR Newswire CAMBRIDGE...
PR Newswire·10mo ago
News Placeholder
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission PR Newswire CAMBRIDGE...
PR Newswire·10mo ago
News Placeholder
EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission
NeuroSense Therapeutics schedules an FDA Type C meeting on Nov. 6 to finalize its Phase 3 trial design for PrimeC, a potential ALS treatment. read more...
Benzinga·10mo ago
News Placeholder
New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients
New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients PR Newswire CAMBRIDGE, Mass., Oct. 24, 2024...
PR Newswire·11mo ago

Latest NRSN News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.